I-Flow to Present at the First Albany Capital Annual Growth Conference Tuesday, December 6, 2005 at 5:20 P.M. EST
Posted on: Thursday, 1 December 2005, 12:00 CST
I-Flow Corporation (NASDAQ:IFLO) announced today that it will address institutional shareholders at the First Albany Capital Annual Growth Conference, Tuesday afternoon, December 6, 2005 at 5:20 p.m. EST.
The First Albany Capital conference will take place December 6th and 7th at The Mandarin Oriental Hotel, New York, NY. Donald M. Earhart, I-Flow's Chairman, President, and Chief Executive Officer, will make a presentation describing the Company's growth strategies, financial outlook and market opportunities for its three businesses.
I-Flow Corporation is an emerging leader in post-surgical pain relief and is redefining recovery following surgery. The Company's ON-Q(R) PainBuster(R) Post-Op Pain Relief System provides targeted pain relief after surgery only where the body needs it, automatically delivering a non-narcotic, pain-numbing medication directly to an incision site for up to five days. The anesthetic is administered through a specially-designed, proprietary catheter inserted by a surgeon during surgery. ON-Q PainBuster is cleared for use by the U.S. Food & Drug Administration (FDA), and is now labeled to reduce pain significantly better than narcotics and to significantly reduce narcotics intake after surgery.
You can access a live webcast of the presentation, after registration, from the Investors link or the Investors' Event Calendar link at www.IFLO.com. The webcast will be available for replay within 10 minutes after the live presentation for 90 days. Audio streams require Windows Media installations.
About I-Flow
I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.
Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes,""anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.
Source: Business Wire
Related Articles
- Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)
- Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs
- Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
- REMINDER: ORLive Presents: Minimally Invasive Heart Valve Surgery -- Reduces the Trauma and Pain Associated With Open-Chest Surgery, Improves Patients Quality of Life
- ORLive Presents: Minimally Invasive Heart Valve Surgery -- Reduces the Trauma and Pain Associated With Open-Chest Surgery, Improves Patients Quality of Life
- Corgentech Pain Drug, 4975, Demonstrates Statistically Significant Pain Reduction After Knee Replacement Surgeries
- Synovics Pharmaceuticals Initiates U.S. Development of Its Third Generic Oral Controlled-Release Drug
- Bionutrics Announces the Initiation of Its Second US Development for a Generic Oral Controlled-Release Drug
- Experts: Evaluate Pain Vs. Gain of Back Surgery
- Kinetics-Effect Relations of Insulin-Releasing Drugs in Patients With Type 2 Diabetes: Brief Overview
User Comments (0)

RSS Feeds